Merck's Keytruda Franchise Expands, Signals 'Modest' Revenue Growth in 2027
Key takeaways
- Merck’s earnings beat and higher , driven by Keytruda growth, lift the stock and suggest steady revenue expansion into 2027.
guidance
What a company says it expects for future sales or profits — a forecast from the company, not a guarantee.
- Adjusted earnings $2.49 per share
- Revenue $18.085 billion
- Keytruda sales $8.6 billion
What happened
Merck & Co. Inc. (MRK) reported third‑quarter earnings that beat expectations, with adjusted earnings of $2.49 per share versus analysts’ $2.08 and revenue of $18.085 billion versus $17.313 billion. The company highlighted growth in its Keytruda franchise, which generated $8.6 billion in global sales, up 6% year‑over‑year, and added $830 million in sales from the new Keytruda Qlex injection. Other highlights included a 14% jump in Gardasil sales to $1.995 billion and a 93% increase in…
Why it matters
The earnings beat and higher What a company says it expects for future sales or profits — a forecast from the company, not a guarantee.guidance
Short-term and longer-term
Short-term. Merck’s shares jumped 5% on the news, reflecting the market’s positive reaction to the earnings beat and higher What a company says it expects for future sales or profits — a forecast from the company, not a guarantee.guidance
Longer-term. The updated What a company says it expects for future sales or profits — a forecast from the company, not a guarantee.guidance
Words on this card
- Keytruda
- Merck’s flagship cancer immunotherapy drug
- Qlex
- A new under‑the‑skin injection format of Keytruda
- Gardasil
- Merck’s HPV vaccine
- Winrevair
- Merck’s treatment for pulmonary arterial hypertension
- Cytokine release syndrome
- An immune reaction that can occur with certain immunotherapies
- Guidance
- What a company says it expects for future sales or profits — a forecast from the company, not a guarantee.